Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup. In its early days, TAVR also showed benefits, but<a href="https://solaci.org/en/2023/10/11/cause-of-cardiac-death-after-tavr-at-present/" title="Read more" >...</a>
ALT FLOW device for left atrial to coronary sinus shunting in symptomatic heart failure patients. In the treatment of heart failure (HF), significant improvement in patient quality of life and prognosis has been achieved through appropriate medical treatment and, in some cases, the use of devices. However, in certain cases, satisfactory clinical improvement cannot be<a href="https://solaci.org/en/2023/07/04/a-new-alternative-for-the-treatment-of-heart-failure-left-atrial-to-coronary-sinus-shunt-with-the-apture-device/" title="Read more" >...</a>
We are already familiar with the strong impact of secondary mitral valve regurgitation (SMR) in survival and quality of life. Most of these patients present heart failure (HF) with reduced ejection fraction (HFrEF). Stages of heart failure based on extra-mitral cardiac involvement has been shown relevant. There is also extensive research on aortic valve disease<a href="https://solaci.org/en/2023/01/09/secondary-mitral-regurgitation-stages-of-heart-failure-and-prognostic-implications-after-transcatheter-edge-to-edge-repair/" title="Read more" >...</a>
This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a complete echocardiogram. Surgical risk was 17.3% extreme/inoperable, 54.3% intermediate and 28.4% low. 60% received transcatheter aortic valve replacement (TAVR) and the rest surgical aortic valve replacement (SAVR). 6.1% of patients were in stage 0 (no damage), 14.5% were<a href="https://solaci.org/en/2022/05/19/europcr-2022-changes-in-cardiac-damage-after-surgical-aortic-valve-replacement/" title="Read more" >...</a>
According to this recent document by the American Heart Association (AHA), troponin should be monitored for at least 3 days after surgery. With about 20% of patients (most of them, asymptomatic) showing elevated troponin after a non-cardiac surgery, this new AHA document recommends monitoring, for at least two days, patients with moderate to severe ischemia. Myocardial<a href="https://solaci.org/en/2021/10/19/more-screening-needed-before-non-cardiac-surgery/" title="Read more" >...</a>
The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2<a href="https://solaci.org/en/2021/09/01/esc-2021-empagliflozin-in-heart-failure-with-reduced-and-preserved-ejection-fraction/" title="Read more" >...</a>
This large cohort of patients undergoing PCI for chronic total occlusion has shown suboptimal recanalization is associated with cardiac death and myocardial infarction at long term compared against procedural failure. The link between acute outcomes and long-term events in recanalizations has been overlooked. Mainly when it comes to suboptimal results, is doing something more trouble<a href="https://solaci.org/en/2020/12/28/suboptimal-recanalization-results-worse-than-procedural-failure/" title="Read more" >...</a>
Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization. These new data resulted from the analysis of the VOYAGER PAD subgroups and were presented at the virtual ESC 2020. The COMPASS study had reached similar conclusions using 2.5 mg rivaroxaban<a href="https://solaci.org/en/2020/09/09/esc-2020-rivaroxaban-might-reduce-cardiac-cerebral-and-peripheral-events/" title="Read more" >...</a>
The DAPA-CKD trial has shown dapagliflozin, a SGLT2 receptor inhibitor, improves function, and reduces cardiovascular events and mortality. The latter is true regardless being or not diabetic. Patients with chronic kidney failure randomized to dapagliflozin saw improved kidney function, reduced cardiovascular events and increased survival rate. Primary end point, a combination of glomerular filtration deterioration<a href="https://solaci.org/en/2020/09/07/esc-2020-dapagliflozin-in-kidney-failure-the-drug-continues-to-conquer-other-territories/" title="Read more" >...</a>
Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in patients with heart failure, even in those without diabetes. Adding empagliflozin to optimal medical therapy lowers the risk of cardiovascular events in patients with heart failure and reduced ejection fraction. Such events include heart failure hospitalization, worsening kidney<a href="https://solaci.org/en/2020/09/03/esc-2020-new-sglt2-inhibitor-impacts-heart-failure-mortality/" title="Read more" >...</a>